PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Trial Details

NCT ID
NCT03647072
Phase
PHASE3
Sponsor
Sherief Abd-Elsalam
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • CHOP
  • CHOP Plus Lanzoprazole
  • CHOP Plus Famotidine
Locations (sample)
  • Cairo, Egypt|30.06263,31.24967

Key Eligibility Criteria

  • DLBCL Lymphoma subtype --No comorbid disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →